ExploreWatchlistsPricing
  1. JP-listed companies
  2. PeptiDream Inc.
  3. Financials
  4. Property, plant and equipment, net

PeptiDream Inc. (4587)

Market cap
¥153.7B
P/E ratio
Peptidream develops new drugs using its proprietary PDPS platform and creates radiopharmaceuticals for diagnosing and treating cancer and other diseases.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndProperty, plant and equipment, net (Million JPY)YoY (%)
Dec 31, 202518,929+8.01%
Dec 31, 202417,526+0.97%
Dec 31, 202317,358-4.23%
Dec 31, 202218,125+181.58%
Dec 31, 20216,437+11.62%
Dec 31, 20205,767+0.56%
Dec 31, 20195,735-1.95%
Jun 30, 20195,849-4.79%
Jun 30, 20186,143+26.51%
Jun 30, 20174,856+54.70%
Jun 30, 20163,139+130.42%
Jun 30, 20151,362+728.02%
Jun 30, 2014165

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat